within Pharmacolibrary.Drugs.ATC.L;

model L01CD02
  extends Pharmacokinetic.Models.PK_3C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00035,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.113,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CD02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Docetaxel is a semisynthetic taxane antineoplastic agent used primarily for the treatment of various cancers including breast, non-small cell lung, prostate, gastric, and head and neck cancer. It acts by promoting and stabilizing microtubule assembly, thereby inhibiting mitosis and cell proliferation. It is an approved chemotherapy drug widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients with normal hepatic function, following intravenous infusion.</p><h4>References</h4><ol><li><p>Rafiei, P, &amp; Haddadi, A (2017). Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. <i>International journal of nanomedicine</i> 12 935–947. DOI:<a href=&quot;https://doi.org/10.2147/IJN.S121881&quot;>10.2147/IJN.S121881</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28184163/&quot;>https://pubmed.ncbi.nlm.nih.gov/28184163</a></p></li><li><p>Marchettini, P, et al., &amp; Sugarbaker, PH (2002). Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. <i>Cancer chemotherapy and pharmacology</i> 49(6) 499–503. DOI:<a href=&quot;https://doi.org/10.1007/s00280-002-0439-1&quot;>10.1007/s00280-002-0439-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12107555/&quot;>https://pubmed.ncbi.nlm.nih.gov/12107555</a></p></li><li><p>Paller, CJ, et al., &amp; Levine, M (2024). High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. <i>Cancer research communications</i> 4(8) 2174–2182. DOI:<a href=&quot;https://doi.org/10.1158/2767-9764.CRC-24-0225&quot;>10.1158/2767-9764.CRC-24-0225</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39076107/&quot;>https://pubmed.ncbi.nlm.nih.gov/39076107</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CD02;
